BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic Adopts Limited Duration Stockholders Rights Plan

Synlogic (SYBX)SynlogicCompany update

Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process CAMBRIDGE, Mass. , Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today

Related news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

EMBCEmbecta2026-05-15 13:00 EST

embecta Completes Acquisition of Owen Mumford Holdings Limited

EMBCEmbecta2026-03-19 10:30 EST

embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Stock data

Close
1.20 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States